Veru Inc

NASDAQ:VERU   3:59:59 PM EDT
14.27
-0.74 (-4.93%)
4:13:42 PM EDT: $14.22 -0.05 (-0.35%)
Products

FDA States That Veru Should Submit Request For Emergency Use Authorization (Eua) Based On Positive Efficacy And Safety Data From The Phase 3 Clinical Study Of Sabizabulin In Hospitalized Covid-1

Published: 05/11/2022 10:40 GMT
Veru Inc (VERU) - FDA States That Veru Should Submit Request for Emergency Use Authorization (eua) Based on Positive Efficacy and Safety Data From the Phase 3 Clinical Study of Sabizabulin in Hospitalized Covid-19 Patients.
Veru Inc - Company Plans to Meet With U.S. and Ex-u.s. Government Officials to Discuss Advance Purchase Agreements.
Veru Inc - a Request for Eua is Planned for Submission in Calendar 2q 2022.
Veru Inc - a Request for Eua is Planned for Submission in Calendar 2q 2022-.
Veru Inc - FDA Agrees That No Additional Efficacy Studies Or Safety Data Are Required to Support a Request for Eua.
Veru Inc - Initiated Discussions With Government Agencies to Discuss Government Purchases of Sabizabulin in U.S. and Other Countries Around World.
Veru Inc - Scaled Up Manufacturing Processes and Will Be Able to Produce Drug Supply Tanticipated Drug Needs Following Potential FDA Authorization.